HK-listed HBM jumps on licensing deal with Solstice on oncology drug

HBM Holdings

23/02/2026 02:22

** Shares of HBM Holdings 2142.HK jump 9.3% to HK$13.38, their highest level since January 20, and on course for a third straight session of gains

** Stock of the Chinese immuno-oncology and immunology diseases therapeutics developer on track for biggest one-day pct gain since August 29

** HBM says it has agreed to grant Solstice Oncology - a clinical-stage biotechnology firm set up by venture capital investors, an exclusive license to develop and commercialise a clinical-stage portfolio asset for tumors treatment HBM4003  outside Greater China

** HBM is eligible to receive upfront consideration valued at $105 million, comprising an upfront cash payment of $50 million, a near-term cash payment of $5 million, and over $50 million of equity interest in Solstice Oncology to be issued and allotted to the company

** HBM is also eligible to receive regulatory and commercial milestone payments of up to $1.1 billion on the achievement of certain future events, and tiered royalties on net sales of HBM4003 outside Greater China

** YTD, stock up 9.3%, Hong Kong Biotech Index .HSBIO up 14.7%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))